Research delivers insight into the Sepsis - Pipeline Review, H1 2017
Sepsis - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Sepsis (Infectious Disease) pipeline landscape.
Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor
Complete report available @ Sepsis - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 6, 1, 60, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 7 molecules, respectively.
Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)
- The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Adrenomed AG Altor BioScience Corp Am-Pharma BV Arch Biopartners Inc. Aridis Pharmaceuticals LLC Asahi Kasei Pharma Corp Astellas Pharma Inc Batu Biologics Inc Biomedica Management Corp Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Cell2B Advanced Therapeutics SA Chiome Bioscience Inc Cilian AG Dr. Franz Kohler Chemie GmbH Endacea Inc Evec Inc Ferring International Center SA Huons Co Ltd Immune Response BioPharma Inc Immunethep SA InflaRx GmbH Inotrem SA Integrated BioTherapeutics Inc Lead Discovery Center GmbH Leading BioSciences Inc Lixte Biotechnology Holdings Inc Merck & Co Inc Navigen Pharmaceuticals Inc Nohla Therapeutics Inc Novartis AG OncoImmune Inc Ono Pharmaceutical Co Ltd Opsona Therapeutics Ltd Peptinov SAS ProThera Biologics Inc Ra Pharmaceuticals Inc Recce Ltd Revimmune LLC Ribomic Inc SciClone Pharmaceuticals Inc SetLance srl Shionogi & Co Ltd Silence Therapeutics Plc SK Biopharmaceuticals Co Ltd Spider Biotech Stemedica Cell Technologies Inc Syntiron LLC TaiRx Inc Takeda Pharmaceutical Company Ltd Therakind Ltd Therashock LLC TiGenix NV VBS Pharmaceuticals
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 07:59
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home